Industry News

Clal Biotechnology Industries Ltd.. The US pharmaceutical giant has decided to acquire Medivation, a Nasdaq-listed company, for $14 billion in cash. The Medivation share price leaped 21% in yesterday's trading as a result."/>
Pfizer's Medivation acquisition boosts Clal Biotech [Globes, Tel Aviv, Israel]
Piramal Enterprises Ltd on Tuesday said it is launching a $1 billion distressed asset investment platform in association with private equity fund Bain Capital Credit. "Once finalized, the platform will invest capital directly into businesses and/or acquire debt of such businesses to drive sensible restructurings. The sponsors believe that there is an over $1 billion investing opportunity in this space over the next few years, "..."/>
Piramal Enterprises announces stressed asset investment fund with Bain Capital [Mint, New Delhi]
Aurobindo Pharma Ltd on Tuesday said fiscal first-quarter profit rose 24% on better sales of generic drugs in US and Europe. Net profit rose to Rs.585.5 crore in the quarter ended June compared to Rs.472.5 crore in the same period last year, while revenue grew 13% to Rs.3, 726 crore. While net profit was above analysts' estimates, revenue came in below expectations."/>
Aurobindo Pharma Q1 net profit rises 24% to Rs585 crore [Mint, New Delhi]
The portable charging station [The San Diego Union-Tribune]
Hemispherx Biopharma Inc. said Tuesday that it has received approval of a new drug application in Argentina for its treatment for chronic fatigue syndrome. The Philadelphia-based biotechnology company said rintatolimod, which has the U.S. trade name Ampligen, will be marketed by GP Pharm, Hemispherx's commercial partner in Latin America. "We believe that rintatolimod is the first drug to receive approval for this indication anywhere in the world," Hemispherx said in a..."/>
BRIEF: Hemispherx's chronic fatigue syndrome drug approved for Argentina [The Philadelphia Inquirer]
Medivation for pounds sterling 10.7 bn. The deal follows months of speculation about possible suitors for San Francisco-based Medivation, which produces prostate cancer treatment Xtandi."/>
Pfizer raid on rival to spark takeovers in drugs sector [Daily Mail, London]
Universal Health Services, Inc. announced today that Steve Filton, Senior Vice President and Chief Financial Officer will present at the Baird 2016 Healthcare Conference in New York, NY, on Wednesday, September 7, 2016 at 4:20 p.m. ET. Filton will also be presenting at the Wells Fargo 2016 Healthcare Conference in Boston, MA on Thursday, September 8, 2016 at 9:20 a.m. ET. A live audio webcast of both presentations will be available on the..."/>
Universal Health Services, Inc. To Present At Two Upcoming Healthcare Conferences
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that the underwriters for the Company’ s previously announced public offering have fully exercised their option to purchase an additional 909,090 shares. All 6,969,696 shares sold in the offering were offered by ACADIA at a price to the public of..."/>
ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Cotiviti Holdings Inc. a leading provider of analytics-driven payment accuracy solutions primarily focused on the healthcare industry, announced today that Ruben J. King-Shaw, Jr., Managing Partner and Chief Investment Officer at healthcare focused private equity firm Mansa Capital, LLC, was elected to Cotiviti’ s Board of Directors as an independent director. "We are very pleased to welcome Ruben to Cotiviti’ s Board,” said David Swift, Chairman of the Board of Directors.“..."/>
Cotiviti Appoints Ruben King-Shaw to Board of Directors
Hill-Rom Holdings, Inc., invites you to listen to a management presentation at the 2016 Wells Fargo Healthcare Conference on Thursday, Sept. 8, 2016, at 1:10 p.m. EDT. The live audio webcast of the presentation can be accessed at cfm. A recorded replay will be available one hour after conclusion of the live event through Oct. 8, 2016.."/>
Hill-Rom to Participate in the 2016 Wells Fargo Healthcare Conference
Catalent, Inc., the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that John Chiminski, President& Chief Executive Officer and Matthew Walsh, Executive Vice President& Chief Financial Officer, will present at the Morgan Stanley Global Health Care Conference at 10:35 a.m. ET on Tuesday, September 13, 2016 in New York City. A live webcast of the presentation..."/>
Catalent, Inc. to Present at the Morgan Stanley Global Health Care Conference
Lannett Company, Inc. today reported financial results for its fiscal 2016 fourth quarter and full year ended June 30, 2016. As previously announced, the company completed the acquisition of Kremers Urban Pharmaceuticals Inc. on November 25, 2015. Accordingly, fiscal 2016 fourth-quarter and full-year financial results include the operations of KU since the acquisition date."/>
Lannett Announces Record Net Sales For Fiscal 2016 Fourth-Quarter And Full-Year
McKesson Corporation today announced that James Beer, the company’ s executive vice president and chief financial officer, will present at the Morgan Stanley Global Healthcare Conference in New York at 10:00 a.m. ET on Tuesday, September 13, 2016. Audio webcasts will be available live and archived on the company’ s Investor Relations website at A complete listing of upcoming events for the investment community is available on..."/>
McKesson Corporation To Present at the Morgan Stanley Global Healthcare Conference
TeamHealth Holdings, Inc. has acquired the operations of California-based group practice Grossmont Emergency Medical Group, the company said. Based in the San Diego area, GEMG provides care to more than 100,000 patients each year through staffing and management of the emergency department at Sharp Grossmont Hospital. Team Health Holdings provides outsourced healthcare professional staffing and..."/>
TeamHealth Acquires Operations of California Group Practice
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing Ethyol ® for injection to U.S. wholesalers today. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer."/>
Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient Support
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a public offering price of $10.00 per share, which includes the exercise in full of the underwriters' right to purchase up to an additional 825,000 shares of common stock."/>
OncoMed Pharmaceuticals Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, announced today that it has been awarded a contract for up to $16.6 million in total funding from the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response’ s Biomedical Advanced Research and Development Authority to advance the Company’ s rapid Zika tests.. The six-year, multi-phased contract..."/>
OraSure Awarded Up to $16.6 Million to Advance Rapid Zika Tests
Waters Corporation and Ireland’ s National Institute for Bioprocessing Research and Training have created a new integrated database called Rapi Fluor-MS™ Glycan GU Scientific Library that enables automated data analysis of N-linked glycans using the Waters ® Glycan Application Solution with UNIFI ®. This Smart News Release features multimedia."/>
Waters and NIBRT Researchers Generate Reference Library for Released N-Glycans Labeled with RapiFluor-MS
Clovis Oncology, Inc. announced today that the U.S. Food and Drug Administration has accepted Clovis’ New Drug Application for accelerated approval of rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act date of February 23, 2017."/>
FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary601 Articles
Information Technology555 Articles
Financials488 Articles
Industrials362 Articles
Health Care311 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at